10-Q: Bio Essence Corp. Reports Net Loss Despite Discontinued Operations Gain in Q2 2024

Bio Essence Corp.'s Q2 2024 results reveal a net loss of $81,740, despite a gain from the disposal of discontinued operations, and the company expresses doubt about its ability to continue as a going concern.

Summary

• Bio Essence Corp. reported a net loss of $81,740 for the six months ended June 30, 2024, compared to a net loss of $463,351 for the same period in 2023.
• The company's continuing operations resulted in a net loss of $338,665 for the first six months of 2024, compared to a net loss of $116,507 in the prior year.
• Revenue from continuing operations was $41,695 for the six months ended June 30, 2024, compared to no revenue in the same period of 2023.
• The company recognized a gain of $377,752 from the disposal of discontinued operations.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
• Management intends to raise funds through private or public offerings or by obtaining loans.
• As of June 30, 2024, the company had a working capital deficit of $2,192,611 and a current ratio of 0.29:1.
• The company's principal source of funds is loans from an officer, who is also a major shareholder.
• The company estimates it needs $1.2 million to continue its current business for the next 12 months.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the net loss, going concern warning, and need for additional funding, although there are some positive aspects such as increased revenue from continuing operations and a gain from discontinued operations.

Positives

• The net loss decreased from $463,351 in the first six months of 2023 to $81,740 in the first six months of 2024.
• Revenue from continuing operations increased to $41,695 for the six months ended June 30, 2024, compared to no revenue in the same period of 2023.
• The company realized a gain of $377,752 from the disposal of discontinued operations.
• The company is actively seeking other business opportunities including expanding OEM business and looking for potential acquisition targets.

Negatives

• The company's continuing operations resulted in a net loss of $338,665 for the first six months of 2024.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company had a working capital deficit of $2,192,611 and a current ratio of 0.29:1 as of June 30, 2024.
• The company needs $1.2 million to continue its current business for the next 12 months.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate sufficient revenue and raise additional funds.
• The company may have difficulty meeting upcoming cash requirements.
• Lack of liquidity could have a material adverse effect on the company's business viability, financial position, results of operations, and cash flows.
• The company's reliance on loans from a major shareholder presents a risk if that funding source becomes unavailable.

Future Outlook

The company plans to increase income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities; management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others.

Management Comments

• Management believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions.
• Management is responsible for establishing and maintaining adequate internal control over financial reporting.

Industry Context

The health supplement industry is competitive, and Bio Essence Corp. faces challenges in generating revenue and maintaining liquidity.

Comparison to Industry Standards

• It is difficult to compare Bio Essence Corp.'s results to industry standards without knowing specific competitors and their financial performance.
• However, the company's negative working capital and low current ratio suggest it is underperforming compared to companies with healthier balance sheets.
• The company's reliance on debt financing from related parties is not uncommon for small businesses but can be a higher-risk strategy than traditional bank financing.

Related Party Transactions

• The Company held loans from one major shareholder (also the Company's senior officer) for $1,365,246 and $1,180,046 at June 30, 2024 and December 31, 2023, respectively.
• The Company held a loan from another major shareholder for $608,631 for settling the litigation at June 30, 2024 and December 31, 2023.
• On May 31, 2023, the Board of Directors of the Company, approved a debt-to-equity conversion where Ms. Yan receives 5,000,000 shares of the Company's common stock in exchange for retirement of the $2,500,000 debt.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises capital through equity offerings.
• Employees' job security is uncertain due to the company's financial difficulties.
• The company's ability to meet its obligations to suppliers and creditors is at risk.

Next Steps

• The company plans to increase its income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities.
• The company will explore options to provide additional financing to fund future operations, including securing lines of credit, sales of debt or equity securities, loans, and cash advances.

Key Dates

Keywords

financial statements, going concern, net loss, discontinued operations, liquidity, revenue, Bio Essence Corp, health supplement products